Newsletter Login

Username:

Password:


Need help logging in?

New Subscriber?
Start Here!

Q & A

What kind of initial investment do we need to get started following one of your recommended lists?



Read More from Q&A


Tools & Resources

Free
30 Day Trial!

Activate Trial

Welcome to Dow Theory Forecasts

Dow Theory Forecasts is written with the busy reader in mind. Weekly stock recommendations and analysis is geared towards the individual investor looking for actionable stock market advice in a "just-the-facts" approach. Twice weekly hotlines with market news, stock upgrades and downgrades keep subscribers informed between issues.

View back issues in the Dow Theory Archive.

From the Current Newsletter:

August 21, 2017 issue

Finding value among record highs

The stock market’s unabated climb may be giving some investors elevation sickness. The S&P 1500 Index, up 9% so far this year, is on pace to post its eighth straight year of gains, generating an annualized total return of roughly 15% during that stretch.

Despite rebounding profit growth in recent quarters, U.S. stocks have rarely been so expensive...

Read the rest of this article for more specific investing advice and stock investment information when you sign up for a FREE 30-day trial to Dow Theory Forecasts.


More Investment Newsletters and Services

Drip Investor

DRIP Investor — how you can buy dividend-paying stocks without a broker.

Visit us at DRIP Investor, your source for dividend reinvestment plans.

Lazy Investor

The Lazy Investor — free weekly e-letter that delivers market updates and stock market information via email.

Visit us at The Lazy Investor, our free investment newsletter.

Horizon Investment

Horizon — registered investment advisor seeks to provide investors at all stages the ability to build, preserve and enjoy wealth.

Visit us at Horizon Investment Services to get started in an investment program that's right for you.

Upside

Upside — discovers today's small and midcap stocks poised to be tomorrow's Blue Chip leaders.

Visit us at Upside, your guide to the best buys in small and midcap stocks.

Current Hotline

Wednesday, August 23, 2017

This is not an ideal time to invest. Bonds and money-market funds offer puny yields

…

Read More from the Hotline

Stock Spotlight

ICON shares worth a trial

Wednesday, August 23, 2017

It takes an estimated $2.6 billion and up to 15 years to develop and win regulatory approval for a new drug, according to the Tufts Center for the Study of Drug Development. With such huge amounts of...

Read More from Stock Spotlight

Individual Stock Reports

ISRs make stock research easy!

Perhaps the most valuable two page reports available anywhere.

All the data you would normally have to plow through years of 10-K filings, earnings reports, and reams of market data to assemble — yours all in one concise report.

ISRs contain our proprietary Quadrix scores — find out how we rate all the stocks in the S&P 500.

Visit us at individualstockreports.com